Cargando…

1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales

BACKGROUND: Plazomicin (PLZ) approved by FDA in June of 2018, is an aminoglycoside class antibacterial indicated for the treatment of adults with complicated urinary tract infections (cUTI) including pyelonephritis caused by Enterobacterales. It is used in patients who have limited or no alternative...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Yun, Armstrong, Tom, Blanchard, Laurine, Kresken, Michael, Zambardi, Gilles, Pompilio, Marion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776453/
http://dx.doi.org/10.1093/ofid/ofaa439.1412
_version_ 1783630686962319360
author Ying, Yun
Armstrong, Tom
Blanchard, Laurine
Kresken, Michael
Zambardi, Gilles
Pompilio, Marion
author_facet Ying, Yun
Armstrong, Tom
Blanchard, Laurine
Kresken, Michael
Zambardi, Gilles
Pompilio, Marion
author_sort Ying, Yun
collection PubMed
description BACKGROUND: Plazomicin (PLZ) approved by FDA in June of 2018, is an aminoglycoside class antibacterial indicated for the treatment of adults with complicated urinary tract infections (cUTI) including pyelonephritis caused by Enterobacterales. It is used in patients who have limited or no alternative treatment options, e.g. CRE and MDRO patients. The drug has bactericidal activity, it is active against organisms producing ESBL, Carbapenemase and aminoglycoside-modifying enzymes. The purpose of this study was to compare ETEST(®) PLZ bioMérieux to the broth microdilution reference method (BMD) for Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca and pneumoniae, Morganella morganii, Providencia stuartii, Proteus mirabilis and vulgaris and Serratia marcescens isolates. METHODS: A total of 598 isolates were tested by ETEST® (PLZ) and BMD at four clinical trial sites. Isolates were subcultured on tryptic soy or Columbia agar plates supplemented with 5% sheep blood. Suspensions of the isolates were prepared in 0.85% saline, which were used to inoculate BMD and Mueller Hinton agar for ETEST(®). Results were read after 16-20 hours incubation at 35°C +2°C in ambient air. QC organisms were tested with each run following CLSI QC guidelines. Results were analyzed using FDA breakpoints for PLZ (Susceptible <2 µg/mL, Intermediate 4 µg/mL, Resistant >8 µg/mL). Performance was evaluated using FDA performance criteria, EA and CA (≥ 90%), major error rate (≤3.0%) and very major error rate (≤2.0%). RESULTS: CONCLUSION: ETEST® PLZ clinical performance met the FDA acceptance criteria and was found useful for determining Plazomicin MIC of Enterobacterales, including ESBL, CRE (MBL, KPC, Oxa-48), high level AmpC and aminoglycoside resistant strains. Percent susceptibility of Plazomicin is at 80% among the 598 isolates tested, the mode MIC is 0.5 ug/ml as Susceptible. DISCLOSURES: Tom Armstrong, BS, bioMérieux (Employee) Laurine Blanchard, PhD, bioMérieux (Employee) Michael Kresken, PhD, bioMérieux (Scientific Research Study Investigator, Research Grant or Support) Gilles Zambardi, biomerieux (Employee) Marion Pompilio, BioMérieux (Employee)
format Online
Article
Text
id pubmed-7776453
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77764532021-01-07 1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales Ying, Yun Armstrong, Tom Blanchard, Laurine Kresken, Michael Zambardi, Gilles Pompilio, Marion Open Forum Infect Dis Poster Abstracts BACKGROUND: Plazomicin (PLZ) approved by FDA in June of 2018, is an aminoglycoside class antibacterial indicated for the treatment of adults with complicated urinary tract infections (cUTI) including pyelonephritis caused by Enterobacterales. It is used in patients who have limited or no alternative treatment options, e.g. CRE and MDRO patients. The drug has bactericidal activity, it is active against organisms producing ESBL, Carbapenemase and aminoglycoside-modifying enzymes. The purpose of this study was to compare ETEST(®) PLZ bioMérieux to the broth microdilution reference method (BMD) for Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca and pneumoniae, Morganella morganii, Providencia stuartii, Proteus mirabilis and vulgaris and Serratia marcescens isolates. METHODS: A total of 598 isolates were tested by ETEST® (PLZ) and BMD at four clinical trial sites. Isolates were subcultured on tryptic soy or Columbia agar plates supplemented with 5% sheep blood. Suspensions of the isolates were prepared in 0.85% saline, which were used to inoculate BMD and Mueller Hinton agar for ETEST(®). Results were read after 16-20 hours incubation at 35°C +2°C in ambient air. QC organisms were tested with each run following CLSI QC guidelines. Results were analyzed using FDA breakpoints for PLZ (Susceptible <2 µg/mL, Intermediate 4 µg/mL, Resistant >8 µg/mL). Performance was evaluated using FDA performance criteria, EA and CA (≥ 90%), major error rate (≤3.0%) and very major error rate (≤2.0%). RESULTS: CONCLUSION: ETEST® PLZ clinical performance met the FDA acceptance criteria and was found useful for determining Plazomicin MIC of Enterobacterales, including ESBL, CRE (MBL, KPC, Oxa-48), high level AmpC and aminoglycoside resistant strains. Percent susceptibility of Plazomicin is at 80% among the 598 isolates tested, the mode MIC is 0.5 ug/ml as Susceptible. DISCLOSURES: Tom Armstrong, BS, bioMérieux (Employee) Laurine Blanchard, PhD, bioMérieux (Employee) Michael Kresken, PhD, bioMérieux (Scientific Research Study Investigator, Research Grant or Support) Gilles Zambardi, biomerieux (Employee) Marion Pompilio, BioMérieux (Employee) Oxford University Press 2020-12-31 /pmc/articles/PMC7776453/ http://dx.doi.org/10.1093/ofid/ofaa439.1412 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Ying, Yun
Armstrong, Tom
Blanchard, Laurine
Kresken, Michael
Zambardi, Gilles
Pompilio, Marion
1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales
title 1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales
title_full 1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales
title_fullStr 1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales
title_full_unstemmed 1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales
title_short 1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales
title_sort 1227. plazomicin susceptibility testing using etest(®) mic for enterobacterales
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776453/
http://dx.doi.org/10.1093/ofid/ofaa439.1412
work_keys_str_mv AT yingyun 1227plazomicinsusceptibilitytestingusingetestmicforenterobacterales
AT armstrongtom 1227plazomicinsusceptibilitytestingusingetestmicforenterobacterales
AT blanchardlaurine 1227plazomicinsusceptibilitytestingusingetestmicforenterobacterales
AT kreskenmichael 1227plazomicinsusceptibilitytestingusingetestmicforenterobacterales
AT zambardigilles 1227plazomicinsusceptibilitytestingusingetestmicforenterobacterales
AT pompiliomarion 1227plazomicinsusceptibilitytestingusingetestmicforenterobacterales